Back to Cell Types

HuH-6Homo sapiens (Human)Cancer cell line

Also known as: Huh6, HUH6, HuH6, HuH 6, HUH-6

🤖 AI SummaryBased on 11 publications

Quick Overview

HuH-6 is a human hepatoma cell line used in cancer research.

Detailed Summary

HuH-6 is a human hepatoma cell line derived from liver cancer tissue. It is commonly used in research to study hepatocellular carcinoma (HCC) and the molecular mechanisms involved in liver cancer development. The cell line has been characterized for its genetic mutations, including p53 gene status and potential associations with hepatitis B virus (HBV) integration. HuH-6 is utilized in studies related to drug sensitivity, gene expression profiling, and the investigation of oncogenic pathways such as the Wnt/β-catenin pathway. Research on HuH-6 contributes to understanding the genetic and molecular basis of liver cancer, aiding in the development of targeted therapies and biomarkers for diagnosis and treatment.

Research Applications

Cancer researchDrug sensitivity profilingGene expression analysisOncogenic pathway investigation

Key Characteristics

p53 gene mutationsHBV integrationWnt/β-catenin pathway activationChemosensitivity to various anticancer drugs

Generated on 6/20/2025

Basic Information

Database ID	CVCL_4381
Species	Homo sapiens (Human)
Tissue Source	Liver[UBERON:UBERON_0002107]

Donor Information

Age	1
Age Category	Pediatric
Sex	Male
Race	asian

Disease Information

Disease	Hepatoblastoma
Lineage	Liver
Subtype	Hepatoblastoma
OncoTree Code	LIHB

DepMap Information

Source Type	RIKEN
Source ID	ACH-000671_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Asn239Asp (c.715A>G)	Heterozygous	-	from parent cell line SNU-475
MutationSimple	TP53	p.Ala159Asp (c.476C>A)	Homozygous	-	PubMed=28683746, PubMed=24755471, PubMed=24042735, PubMed=16418264, PubMed=9000147, PubMed=7651727
MutationSimple	CTNNB1	p.Gly34Val (c.101G>T)	Unspecified	-	Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

10,12

D13S317

8,12

D16S539

10,11

D18S51

13,21

D19S433

12,12.2

D21S11

29,30

D2S1338

18

D3S1358

14,17

D5S818

8,11

D7S820

11,12

D8S1179

10,11

FGA

19,24

TH01

7,8

TPOX

8

vWA

14,17

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

RNA sequencing of hepatobiliary cancer cell lines: data and applications to mutational and transcriptomic profiling.

Umu S.U., Rounge T.B., Roessler S., Lorenzo-Bermejo J.

Cancers (Basel) 12:2510.1-2510.14(2020).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.

Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.

Gastroenterology 157:760-776(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.

Nat. Commun. 4:2218.1-2218.7(2013).

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.

Xu J.-C.

Hepatology 58:706-717(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell lines by WNT/beta-catenin pathway, microRNA expression and protein expression profile.

Macino G., Tanzarella C., Taruscio D.

Cell. Mol. Biol. 56:OL1299-OL1317(2010).

Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.

Yamori T.

Mol. Cancer Ther. 4:399-412(2005).

Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas.

Soubrane O., Fabre M., Chelly J., Beldjord C., Kahn A., Perret C.

Proc. Natl. Acad. Sci. U.S.A. 95:8847-8851(1998).

Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.

Fukaya K.-i., Ishioka C., Namba M.

Acta Med. Okayama 51:261-265(1997).

p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.

Harris C.C.

Carcinogenesis 14:987-992(1993).

Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma.

Doi I.

Gann 67:1-10(1976).

The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.

Ohashi R., Namba M.

Tissue Cult. Res. Commun. 16:173-178(1997).

Cellular characteristics and utilization of human hepatoma cell lines which were established in our laboratory and distributed by Japanese Cancer Research Resources Bank.

Namba M., Nakabayashi H., Doi I., Sato J., Miyazaki M.

Tissue Cult. Res. Commun. 12:221-227(1993).

Web Resources

lccl.zucmanlab.com